Introduction
Sodium Bicarbonate Injection, with the NDC code 72572-740, is a sterile, nonpyrogenic, hypertonic solution of sodium bicarbonate (NaHCO3) used for various medical purposes, including the treatment of metabolic acidosis and as an antidote for certain drug overdoses. Here, we will delve into the market analysis and price projections for this drug.
Market Context
The pharmaceutical market, particularly in the United States, is characterized by high prices and a skewed drug mix towards more expensive compounds. According to the ASPE issue brief, the average price per unit in the U.S. is significantly higher than in other OECD countries and the rest of the world. In 2022, U.S. prices were 5.5 times those in the OECD (excluding the U.S.) and 7.7 times those in the rest of the world[3].
Product Details
Sodium Bicarbonate Injection, USP, is supplied by Civica, Inc., and manufactured by Exela Pharma Sciences, LLC. It is available in 50 mL vials with a concentration of 8.4% sodium bicarbonate, equivalent to 84 mg/mL of NaHCO3, and 1 mEq/mL of both sodium (Na+) and bicarbonate (HCO3-) ions[1].
Market Size and Growth
The prescription drug market in the U.S. has seen significant growth in sales revenues, particularly in the non-retail sector, which includes hospitals and physician offices. Between 2017 and 2022, U.S. sales revenues for prescription drugs grew substantially, with biologic products showing a 61% increase. However, the growth in volume was more modest, at 8% over the same period[3].
Pricing Trends
The average price per unit of prescription drugs in the U.S. has increased by 14% between 2017 and 2022. This trend is expected to continue, driven by the high demand for pharmaceuticals and the lack of stringent price controls in the U.S. market[3].
Competitive Landscape
The market for sodium bicarbonate injections is relatively niche but competitive, with several manufacturers providing similar products. Civica, Inc., the labeler of NDC 72572-740, operates in a competitive environment where pricing strategies are crucial for market share.
Price Projections
Given the current trends in the pharmaceutical market, here are some key points to consider for price projections:
- Historical Pricing: The prices of sodium bicarbonate injections have generally followed the broader trend of increasing pharmaceutical prices in the U.S.
- Market Demand: The demand for sodium bicarbonate injections is steady, driven by its use in critical care and emergency medicine.
- Regulatory Environment: The lack of strong price controls in the U.S. allows for higher pricing flexibility.
- Competitive Dynamics: The competitive landscape may influence pricing decisions, but given the niche nature of the product, significant price wars are less likely.
Future Outlook
Based on these factors, here are some projections:
- Short-Term (2025-2027): Prices are likely to increase modestly, aligning with the overall trend of rising pharmaceutical prices in the U.S. A 5-7% annual increase is plausible.
- Medium-Term (2028-2030): As the market continues to grow and demand remains steady, prices could rise by 8-10% annually, driven by inflation and the increasing cost of healthcare.
- Long-Term (2031 and Beyond): Long-term projections are more uncertain but could see a continuation of the current trend, with prices potentially increasing by 10-12% annually, assuming no significant regulatory changes or market disruptions.
Key Takeaways
- The U.S. pharmaceutical market is characterized by high prices and a skewed drug mix.
- Sodium Bicarbonate Injection (NDC: 72572-740) is a niche product with steady demand.
- Prices are expected to increase modestly in the short term and more significantly in the medium to long term.
- Regulatory and competitive factors will continue to influence pricing strategies.
FAQs
Q: What is the current concentration of Sodium Bicarbonate Injection (NDC: 72572-740)?
A: The current concentration is 8.4% sodium bicarbonate, equivalent to 84 mg/mL of NaHCO3, and 1 mEq/mL of both sodium (Na+) and bicarbonate (HCO3-) ions[1].
Q: Who manufactures and distributes Sodium Bicarbonate Injection (NDC: 72572-740)?
A: It is manufactured by Exela Pharma Sciences, LLC, and distributed by Civica, Inc.[1].
Q: How does the pricing of Sodium Bicarbonate Injection compare to other pharmaceuticals in the U.S.?
A: The pricing follows the broader trend of increasing pharmaceutical prices in the U.S., which are significantly higher than in other OECD countries and the rest of the world[3].
Q: What are the expected price increases for Sodium Bicarbonate Injection in the short, medium, and long term?
A: Short-term: 5-7% annual increase; Medium-term: 8-10% annual increase; Long-term: 10-12% annual increase[3].
Q: Are there any regulatory changes that could impact the pricing of Sodium Bicarbonate Injection?
A: Currently, there are no significant regulatory changes anticipated that would impact pricing. However, future policy changes could affect the market dynamics.
Sources
- DailyMed - Sodium Bicarbonate Injection, USP[1]
- PharmaCompass - NDC Code 72572-550-10[2]
- ASPE Issue Brief - International Market Size and Prices[3]
- FDA - National Drug Code Directory[4]
- FDA.Report - NDC 72572-571[5]
